Progenics Pharmaceuticals Inc.

(PGNX) Trade

By |

Profile

Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.

Contact Information

Website: www.progenics.com
Email: investor.relations@progenics.com
Main Phone: +1 646 975-2500
Address: One World Trade Center
Address 2: Suite J, 47th Floor
State: NY
City / Town: New York
Country: USA
Postal Code: 10007

Issuer Information

Exchange: NGS
CEO: David W. Mims
Employees: 79
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

View More

Profile

Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.

Contact Information

Website: www.progenics.com
Email: investor.relations@progenics.com
Main Phone: +1 646 975-2500
Address: One World Trade Center
Address 2: Suite J, 47th Floor
State: NY
City / Town: New York
Country: USA
Postal Code: 10007

Issuer Information

Exchange: NGS
CEO: David W. Mims
Employees: 79
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

View More
$ 5.01 $ -0.13 (-2.53%)
Last Price 5.01 Change $ -0.13 Change % -2.53 Tick N/A
Bid 5.00 Bid Size 200.00 Ask 5.31 Ask Size 200.00
Open 5.09 High 5.18 Low 4.98 Prev Close 5.14
Last Trade Volume 481,735 52 Wk Hi 6.31 52 Wk Low 3.42
Market Cap 433 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 86,421,634.00 EPS (TTM) -0.84 PE Ratio N/A Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 0 0
Number of Buys 0 0
Number of Sells 0 0
Net Activity 0 0
Last 10 Buys Shares
Mark R. Baker 1,000
Mark R. Baker 1,000
Mark R. Baker 1,000
Mark R. Baker 1,000
Mark R. Baker 1,000
Mark R. Baker 1,000
Mark R. Baker 1,000
Mark R. Baker 1,000
Mark R. Baker 1,000
Mark R. Baker 1,000
Last 10 Sell Shares
Kevin Kotler 1,000
Kevin Kotler 1,000
Kevin Kotler 1,000
Kevin Kotler 1,000
Kevin Kotler 1,000
Kevin Kotler 1,000
Kevin Kotler 1,000
Kevin Kotler 1,000
Kevin Kotler 1,000
Kevin Kotler 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 15 15 15 15
Low Target Price Estimate 12 12 12 12
Mean Target Price Estimate 13.5 13.5 13.5 13.5
Standard Deviation 2.12 2.12 2.12 2.12
Date of Most Recent Estimate 05/22/18 05/22/18 05/22/18 05/22/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 3 3 3 2
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1 1 1 1